Halozyme Therapeutics Inc (HALO)

9.29
0.05 0.54
NASDAQ : Health Care
Prev Close 9.24
Open 9.30
Day Low/High 9.11 / 9.38
52 Wk Low/High 6.96 / 25.00
Volume 701.59K
Avg Volume 1.47M
Exchange NASDAQ
Shares Outstanding 129.14M
Market Cap 1.21B
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Under $10 Are Set to Soar

These 5 Stocks Under $10 Are Set to Soar

Here's a technical look at how to trade five stocks trading for less than $10 a share.

Halozyme Therapeutics (HALO) Is Today's Dead Cat Bounce Stock

Halozyme Therapeutics (HALO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)

Today's Dead Cat Bounce Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance

- Interest-only repayment provision results in $44 million increase to expected cash balance through 2017-

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a weak on high relative volume candidate

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20

- Data presented today at American Society of Clinical Oncology Annual Conference Supports Ongoing Phase 3 HALO 301 Clinical Study -

July 15th Options Now Available For Halozyme Therapeutics (HALO)

July 15th Options Now Available For Halozyme Therapeutics (HALO)

Investors in Halozyme Therapeutics Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new July 15th contracts and identified one put and one call contract of particular interest.

Strong On High Volume: Halozyme Therapeutics (HALO)

Strong On High Volume: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Today's Weak On High Volume Stock: Halozyme Therapeutics (HALO)

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a weak on high relative volume candidate

I'm Not Sure I Trust a Market That Uranium Heats

Yet, admittedly, they tried to take ‘em down on Friday and couldn’t.

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment

Adenosine Targeting Immune-Checkpoint Inhibitor and Anti-EGFR Antibody-Drug Conjugate Demonstrate Tumor Growth Inhibition in Pre-Clinical Studies

Halozyme Therapeutics (HALO) Is Today's Strong On High Volume Stock

Halozyme Therapeutics (HALO) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a strong on high relative volume candidate

Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a strong on high relative volume candidate

Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference

Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference

Abstracts include the first data from two novel Halozyme-developed pipeline assets and continued research on the pan-tumor and pan-therapy potential of lead investigational agent, PEGPH20

Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

--FDA Approves Investigational Device Exemption (IDE) For Selection of Patients with HA-High Tumors--

Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a weak on high relative volume candidate

First Week of HALO April 15th Options Trading

First Week of HALO April 15th Options Trading

Investors in Halozyme Therapeutics Inc saw new options begin trading this week, for the April 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HALO options chain for the new April 15th contracts and identified one put and one call contract of particular interest.

8 Biotech Stocks Under $10 Poised for Breakouts

8 Biotech Stocks Under $10 Poised for Breakouts

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

Halozyme Therapeutics (HALO) Highlighted As Weak On High Volume

Halozyme Therapeutics (HALO) Highlighted As Weak On High Volume

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a weak on high relative volume candidate

Halozyme Therapeutics (HALO) Is Strong On High Volume Today

Halozyme Therapeutics (HALO) Is Strong On High Volume Today

Trade-Ideas LLC identified Halozyme Therapeutics (HALO) as a strong on high relative volume candidate